The RENEWAL (Randomized Etanercept Worldwide Evaluation) analysis of the RECOVER and RENAISSANCE trials using etanercept, a soluble TNF-α receptor, to antagonize the harmful effects of TNF-α, failed to meet the primary endpoint addressing all-cause mortality or hospitalization for HF [59]. This evidence concerns the gene TNF and hydrops fetalis.